Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are chronic inflammatory dermatoses that can be a challenge to treat. A role for TNF-alpha in their pathogenesis has been postulated in the literature. A therapeutic benefit of infliximab has been reported in recalcitrant cases of both conditions. To date, there is less evidence about the use of adalimumab for these conditions. We report a patient with severe superficial PG on a background of HS, which responded to adalumimab therapy after failure of infliximab therapy.
Reddick
C L
CL
The Dermatology Centre, University of Manchester, Salford Royal Foundation Hospital, Manchester, United Kingdom.
Singh
M N
MN
Chalmers
R J G
RJ
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015897:Comorbidity; D016572:Cyclosporine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D017497:Hidradenitis Suppurativa / Q000150:complications*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D008911:Minocycline / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D013792:Thalidomide; D016572:Cyclosporine; D003622:Dapsone; D011239:Prednisolone; D000069285:Infliximab; D000068879:Adalimumab; D008911:Minocycline; D008775:Methylprednisolone